Through bioinformatic analyses, we found that intra-tumoral expression of two HPTM enzymes was highly correlated with the survival of HCC patients exposed to the TKI sorafenib; high EZH2 expression and low SETD2 expression were both associated with worse prognosis. This evidence concerns the gene EZH2 and hepatocellular carcinoma.